Lv59
1066 积分 2023-06-27 加入
TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer
5天前
已完结
Immunotherapy resistance in triple-negative breast cancer: Mechanisms and emerging therapeutic strategies
5天前
已完结
Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
5天前
已完结
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
18天前
已完结
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
19天前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
19天前
已完结
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
19天前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
19天前
已完结
Upregulation of Trop-2 quantitatively stimulates human cancer growth
21天前
已完结
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
25天前
已完结
皖公网安备34019202002308
